Singapore to produce new bird flu vaccine

Singapore pharmaceutical giant Baxter Healthcare on Nov. 22 released the preliminary findings for a clinical trial of a new bird flu vaccine.

Singapore pharmaceutical giant Baxter Healthcare on Nov. 22 released the preliminary findings for a clinical trial of a new bird flu vaccine.

Channel NewsAsia reported that the vaccine developed by Baxter can be used on different strains of the H5N1 virus.

The trial was conducted on healthy adults in Austria and Singapore . Side effects from the vaccine are also minor, such as fatigue, headaches and a slight fever, according to the report.

The vaccine is also unique because it can be produced using a cell-base system instead of an egg-base system.

Baxter will conduct further tests before they actively market the vaccine to governments, Channel NewsAsia said.

(Source: VNA)